Absci initiated with a Buy at JonesResearch

JonesResearch analyst Debanjana Chatterjee initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci’s artificial intelligence-driven platform can design antibodies to precisely target an epitope with optimized interface contacts to ensure high potency and affinity, the analyst tells investors in a research note. The firm says the company sets itself apart from competitors with its large scale proprietary training data, zero-shot generative AI model for de novo antibody design, and integrated high throughput in house wet lab screening and validation capacity.